NEW YORK (GenomeWeb News) – Diagnostic test provider Quidel said last week that it has signed an exclusive, worldwide license for the MChip microarray-based influenza detection technology developed by scientists at the University of Colorado and the US Centers for Disease Control and Prevention.
 
The company said it plans to develop and market molecular-based diagnostic tests based on the MChip for use in pandemic surveillance, as a tool for clinical labs, and for point-of-care use in physicians’ offices.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.